EUS-guided Radiofrequency Ablation of locally advanced Pancreatic cancer versus standard treatment (ERAP)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20180706001

Enrollment

Registered

2018-07-06

Start date

2017-08-14

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

For unresectable solid pancreatic lesions pancreatic cancer

Interventions

EUS RFA plus Chemotherapy,Chemotherapy alone

Treatment,Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Malignant Pancreatic Mass 2. Size of Mass is not more than 50mm 3. Concomitant chemotherapy wtihin 4 weeks 4. Expected survival time longer than 3 months

Exclusion criteria

Exclusion criteria: 1. Undergoing radiotherapy 2. ECOG score of more than 2 3. Pregnancy 4. On active heparin or anticoagulant therapy

Design outcomes

Primary

Measure	Time frame
delta of tumor diameter before and after treatment in patients receiving EUS RFA plus CMT versus CMT alone 3 months millimeter	—

Secondary

Measure	Time frame
Tumor necrosis 3 months Necrosis of tumor demonstrated by radiological examination	—

Countries

Thailand

Contacts

Public ContactPradermchai Kongkam

Chulalongkorn University

kongkam@hotmail.com026494003

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026